Obsidian’s cytoDRiVE Discovery Platform has identified a growing library of internally discovered DRDs of varying sizes and intended purposes, and enables rapid optimization of regulatable and functional proteins in any cell type. Our lead clinical program, amsoki-cel, is an investigational TIL cell therapy engineered to express membrane-bound IL15 (mbIL15), which is designed to support TIL activity with the goal of improving depth and durability of response. From company websiteSource · Oct 13, 2026
Keywords: drdscell therapymbil15Tumor SkinMetastatic MelanomaMelanomaLung CancerMetastatic Lung CancerNon Small Cell Lung CancerMetastatic Non Small Cell Lung CancerOBX-115
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.